Milestone (MIST) Alert: Johnson Fistel Launches Investigation into Milestone Pharmaceuticals Inc.; Investors Suffering Losses Encouraged to Contact Firm
SAN DIEGO, March 23, 2020,/PRNewswire/
Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Milestone Pharmaceuticals Inc. (NASDAQ: MIST) (“Milestone or the “Company”) for violations of federal securities laws.
On or about May 9, 2019, Milestone sold about 5.5 million shares of stock in its initial public stock offering (the “IPO”), at $15.00 a share raising approximately $82,500,000 in new capital. However, since the IPO, Milestone stock has plunged, on March 23, 2020, in after-market trading shares traded as low as $2.70 on heavy volume.
Specifically, Johnson Fistel’s investigation seeks to determine whether the Company’s filings with the U.S. Securities and Exchange Commission in connection with its May 2019 IPO and subsequent investor communications contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the Company’s business, and operations.
If you have information that could assist in this investigation, or if you are a Milestone shareholder and are interested in learning more about the investigation, please contact Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.
Additionally, you can [Click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.